A Phase 3 Single-arm Multicenter Study to Evaluate the Efficacy and Safety of UGN-103 a Novel Formulation of UGN-102 for the Treatment of Patients With Low Grade (LG) Nonmuscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence (UTOPIA)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Bladder Cancer
  • Age: Between 18 Year(s) - 99 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Patient who has LG NMIBC (Ta) histologically
    2. History of at least 1 prior episode of NMIBC
    3. Negative voiding cytology for HG disease within 8 weeks before Screening

You may not be eligible for this study if the following are true:

    1. Received BCG treatment for UC within the previous 1 year
    2. History of HG bladder cancer (papillary or CIS) in the past 2 years
    3. Known allergy or sensitivity to any component of the study treatment
    4. Receipt of intravesical chemotherapy within the past 2 years except single instillation following TURBT



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.